Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL-AF Study Design.

Bacare B, Bukhari S, Watson NW, Malejczyk J, Amalan C, Rashedi S, Pfeferman MB, Weber B, Patel S, Ruff C, Kanthi Y, Cushman M, Knight J, Goldhaber SZ, Costenbader K, Mize R, Uljon S, Albert CM, Lip GYH, Krumholz HM, Piazza GM, Bikdeli B

Open source

DOI: 10.1055/a-2899-3848
Published: 2026 Aug 24
Container: Thrombosis and haemostasis
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1055/a-2899-3848,
  title = {Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL-AF Study Design.},
  author = {Bacare B and Bukhari S and Watson NW and Malejczyk J and Amalan C and Rashedi S and Pfeferman MB and Weber B and Patel S and Ruff C and Kanthi Y and Cushman M and Knight J and Goldhaber SZ and Costenbader K and Mize R and Uljon S and Albert CM and Lip GYH and Krumholz HM and Piazza GM and Bikdeli B},
  year = {2026},
  journal = {Thrombosis and haemostasis},
  doi = {10.1055/a-2899-3848},
  url = {https://doi.org/10.1055/a-2899-3848}
}

RIS

TY  - JOUR
TI  - Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL-AF Study Design.
AU  - Bacare B
AU  - Bukhari S
AU  - Watson NW
AU  - Malejczyk J
AU  - Amalan C
AU  - Rashedi S
AU  - Pfeferman MB
AU  - Weber B
AU  - Patel S
AU  - Ruff C
AU  - Kanthi Y
AU  - Cushman M
AU  - Knight J
AU  - Goldhaber SZ
AU  - Costenbader K
AU  - Mize R
AU  - Uljon S
AU  - Albert CM
AU  - Lip GYH
AU  - Krumholz HM
AU  - Piazza GM
AU  - Bikdeli B
PY  - 2026
JO  - Thrombosis and haemostasis
DO  - 10.1055/a-2899-3848
UR  - https://doi.org/10.1055/a-2899-3848
ER  -

APA

B, B., S, B., NW, W., J, M., C, A., S, R., MB, P., B, W., S, P., C, R., Y, K., M, C., J, K., SZ, G., K, C., R, M., S, U., CM, A., GYH, L., HM, K., GM, P., & B, B. (2026). Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL-AF Study Design.. Thrombosis and haemostasis. https://doi.org/10.1055/a-2899-3848

Source records

pubmed · retrieved 2026-09-25T13:40:31.530Z